Qualigen Therapeutics Stock Today
| QLGN Stock | USD 3.22 0.08 2.55% |
PerformanceVery Weak
| Odds Of DistressVery High
|
Qualigen Therapeutics is selling at 3.22 as of the 21st of March 2025; that is 2.55 percent increase since the beginning of the trading day. The stock's open price was 3.14. Qualigen Therapeutics has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 21st of December 2024 and ending today, the 21st of March 2025. Click here to learn more.
Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California. Qualigen Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 736.43 K outstanding shares of which 88.94 K shares are at this time shorted by private and institutional investors with about 0.94 trading days to cover. More on Qualigen Therapeutics
Moving together with Qualigen Stock
Moving against Qualigen Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Qualigen Stock Highlights
| Interim CEO | Kevin II |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) |
Qualigen Therapeutics (QLGN) is traded on NASDAQ Exchange in USA. It is located in 5857 Owens Avenue, Carlsbad, CA, United States, 92008 and employs 4 people. Qualigen Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 2.3 M. Qualigen Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 736.43 K outstanding shares of which 88.94 K shares are at this time shorted by private and institutional investors with about 0.94 trading days to cover.
Qualigen Therapeutics currently holds about 6.62 M in cash with (10.3 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.57.
Check Qualigen Therapeutics Probability Of Bankruptcy
Ownership AllocationQualigen Therapeutics holds 3.77 pct. of its outstanding shares held by insiders and 1.46 pct. owned by third-party entities.
Check Qualigen Ownership Details
Qualigen Therapeutics Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Qualigen Therapeutics market risk premium is the additional return an investor will receive from holding Qualigen Therapeutics long position in a well-diversified portfolio.
| Risk Adjusted Performance | (0.06) | |||
| Jensen Alpha | (0.31) | |||
| Total Risk Alpha | 0.0168 | |||
| Treynor Ratio | (0.79) |
Qualigen Stock Against Markets
Qualigen Therapeutics Corporate Management
| Christopher Lotz | VP Secretary | Profile | |
| MD MBA | Senior Officer | Profile | |
| Amy Broidrick | Chief Pres | Profile | |
| Wajdi AbdulAhad | VP Officer | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Qualigen Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in Qualigen Stock, please use our How to Invest in Qualigen Therapeutics guide.You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Qualigen Therapeutics. If investors know Qualigen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Qualigen Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Qualigen Therapeutics is measured differently than its book value, which is the value of Qualigen that is recorded on the company's balance sheet. Investors also form their own opinion of Qualigen Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Qualigen Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Qualigen Therapeutics' market value can be influenced by many factors that don't directly affect Qualigen Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Qualigen Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Qualigen Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Qualigen Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.